Quarterly ResultAug 6, 2026, 06:17 AM
Generate Biomedicines H1 Net Loss $129.0M; Revenue $13.5M
AI Summary
Generate Biomedicines reported a net loss of $129.0 million for the six months ended June 30, 2026, an increase from $101.1 million in the prior year, while collaboration revenue decreased to $13.5 million. The company significantly improved its liquidity position by completing an initial public offering in March 2026, raising $369.3 million in net proceeds. This funding has alleviated previous concerns about its ability to continue as a going concern, with current capital expected to fund operations into the first half of 2028.
Key Highlights
- Net loss for the six months ended June 30, 2026, was $129.0 million, up from $101.1 million in 2025.
- Collaboration revenue for the six months ended June 30, 2026, was $13.5 million, down from $18.9 million in 2025.
- Cash, cash equivalents, and marketable securities totaled $457.4 million as of June 30, 2026.
- Accumulated deficit reached $805.0 million as of June 30, 2026.
- The company completed an IPO in March 2026, raising net proceeds of approximately $369.3 million.
- The IPO alleviated prior 'going concern' doubts, with sufficient cash expected into the first half of 2028.
- A one-for-1.5190 reverse stock split was effected in February 2026.
Price Impact
More from GENB